ClinicalTrials.gov
public full text
Public Domain
Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors
Describe the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan in cancer patients with advanced solid tumors with UGT1A1 6/6 and 6/7 genotypes.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors#811056
- Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric Cancer#917118
- PRO1107 in Patients With Advanced Solid Tumors#852344
- Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer#1161607
- A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity#1337516
Record · ID 1323313
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive